Overview of HIV Prevention

  • Author: Sharon L. Hillier, PhD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 8/24/18 (What's New)

Summary

  • Injectable formulations of antiretroviral drugs could improve the efficacy of PrEP by enhancing adherence
  • Sustained-release formulations of rilpivirine and cabotegravir are under investigation[Jackson 2012; Markowitz 2017]
  • A dapivirine-containing vaginal ring reduces rate of HIV infection by approximately 30% in 2 phase III clinical trials[Baeten 2016b; Nel 2016]

Action required

Keywords: Biomedical Prevention

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.